Drugs / IMU-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04432207 | Nov 2020 → Oct 2024 | lung adenocarcinoma, lung large cell carcinoma, non-small cell squamous lung carcinoma | Imugene Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMU-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04432207 ↗ |
| Route | Intramuscular | “IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm” NCT04432207 ↗ |